Zealand Pharma (CPSE:ZEAL) Stock Can Obesity Progress Outrun Milestone Driven Earnings?

Zealand Pharma stock came into today on a strong run, up 22% over the past month and 10% over three months, with investors leaning into its low 3.7x P/E and fresh profitability over the last year. The earnings release keeps that tension front and center. H1 revenue landed at DKK 4.5b, powered by a DKK 3.7b Phase III milestone and a DKK 798m payment from Roche, and management highlighted DKK 14.5b of cash on hand. The question now is how long that earnings and cash firepower can support the story, as current forecasts suggest declines ahead.

Love Zealand Pharma's low P/E and cash position but uneasy about forecasts that point to weaker earnings ahead? Compare it with other companies that pair solid balance sheets with stronger fundamentals using our list of solid balance sheet and fundamentals stocks (429 results).

Q2 2026 Earnings Summary

• Revenue (Q1 2026 vs. Q1 2025): DKK 34 million vs. DKK 8 million (increase of 325%)
• Net Income or Loss (Q1 2026 vs. Q1 2025): loss of DKK 394 million vs. loss of DKK 335 million (loss widened by 17.6%)
• Basic EPS (Q1 2026 vs. Q1 2025): loss of DKK 5.58 per share vs. loss of DKK 4.74 per share (loss per share widened by 17.7%)
• Pipeline Breadth (Q3 2025 vs. Q2 2025): 3 products in Phase I, 1 in Phase II, 3 in Phase III and 1 in Pre Registration vs. 2 in Phase I, 2 in Phase II, 4 in Phase III and none in Pre Registration (shift in late stage and earlier stage mix)

Prefer clear visuals over another dense block of earnings tables and footnotes? View Zealand Pharma's full financial picture, including its valuation profile, in our company report for Zealand Pharma.

Zealand Pharma’s Obesity Story Clears Key Proof Points

The bullish idea around Zealand Pharma is that it can turn a focused obesity and metabolic pipeline into a durable, multi asset franchise rather than a single drug bet. The H1 update gives hard evidence that this is starting to happen. Petrelintide now has Phase 2 ZUPREME 1 data with sustained double digit weight loss through 42 weeks and placebo like gastrointestinal tolerability, which is exactly the kind of profile needed for a chronic, first line weight management role. Management has committed to a Phase 3 start in H2 2026, so the obesity thesis is now anchored in a registrational plan, not just mid stage data.

On top of that, partner Boehringer Ingelheim’s survodutide program is hitting clinical and metabolic goals in SYNCHRONIZE 1 and SYNCHRONIZE MASLD, triggering milestone revenue and supporting the idea of multiple shots on goal within obesity and related liver disease.

Compare Zealand Pharma’s expanding obesity pipeline and recent milestone cash inflows with how institutional analysts are sizing up the stock after the latest DKK341.2 close. Reveal whether the Street thinks this operational progress justifies more upside by checking the consensus price target analysis for Zealand Pharma.

Zealand Pharma Bears Focus On Earnings Quality Gaps

The bearish view on Zealand Pharma is that earnings are fragile because they lean on a few partnered assets, chunky milestones and high R&D requirements. The H1 print gives that criticism some traction. The DKK 4.5b of revenue is heavily concentrated in a DKK 3.7b Phase III milestone and a DKK 798m Roche payment, which are not recurring. At the same time, Q1 2026 still showed a loss of DKK 394m with loss per share widening to DKK 5.58, so operating leverage from the obesity platform is not yet visible.

Bears also worry about execution risk and a thin near term catalyst path. Petrelintide’s Phase 3 start and ZUPREME 2 data are both pushed into H2 2026, and key survodutide readouts are also clustered in 2026. That timing means this report does little to clear near term earnings volatility or concentration concerns.

After clustered 2026 trial catalysts and recent earnings volatility, are these issues isolated or early signals of deeper structural problems? Review our full risk analysis for Zealand Pharma which shows 2 important warning signs

Stay Ahead With Simply Wall St

If Zealand Pharma’s mix of milestone driven earnings and obesity pipeline progress has your attention, register for free with Simply Wall St and add it to your Watchlist to track price moves against fair value estimates and wait for an entry point that fits your plan. Once you are invested, keep on top of position size, valuation changes and key news through the Portfolio Command Center so you focus on signals, not noise. For a broader view of what other investors are seeing in Zealand Pharma and similar stocks, tap into the Community to compare theses and sentiment. Spot potential catalysts and red flags early, and focus on staying a step ahead of the market.

Seeking Alternatives Beyond Zealand Pharma?

Fresh ideas do not stay under the radar for long. Spot companies building real momentum before the crowd catches on and before the best entry points are gone.

• Spot sturdy compounders that can handle shocks and still keep moving by scanning our curated group of 295 resilient stocks with low risk scores while that resilience is still underpriced.
• Focus on the infrastructure backbone behind AI’s development by tracking carefully filtered 55 AI infrastructure stocks before institutional money fully catches on and changes the opportunity.
• Look at companies linked to the next leg of industrial demand with a hand picked 9 top copper producer stocks set that could react quickly once momentum returns to key supply chains.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com